Simon Quick Advisors LLC Takes $208,000 Position in Qiagen N.V. $QGEN

Simon Quick Advisors LLC acquired a new stake in shares of Qiagen N.V. (NYSE:QGEN) during the second quarter, Holdings Channel.com reports. The fund acquired 4,334 shares of the company’s stock, valued at approximately $208,000.

A number of other hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in shares of Qiagen by 12.2% during the first quarter. Wellington Management Group LLP now owns 24,438,441 shares of the company’s stock valued at $972,191,000 after purchasing an additional 2,656,136 shares during the period. Deutsche Bank AG raised its stake in shares of Qiagen by 57.5% during the first quarter. Deutsche Bank AG now owns 4,491,131 shares of the company’s stock valued at $180,319,000 after purchasing an additional 1,639,621 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Qiagen by 3,030.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,470,728 shares of the company’s stock valued at $179,501,000 after purchasing an additional 4,327,934 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Qiagen by 11.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,732,963 shares of the company’s stock valued at $131,756,000 after purchasing an additional 287,322 shares during the period. Finally, Caisse Des Depots ET Consignations raised its stake in shares of Qiagen by 7.3% during the first quarter. Caisse Des Depots ET Consignations now owns 1,345,657 shares of the company’s stock valued at $53,374,000 after purchasing an additional 91,357 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of QGEN opened at $44.13 on Wednesday. Qiagen N.V. has a 1 year low of $37.63 and a 1 year high of $51.88. The company has a market cap of $9.81 billion, a price-to-earnings ratio of 26.07, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.35 and a current ratio of 1.61. The firm has a fifty day moving average of $46.66 and a 200-day moving average of $46.48.

Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.03. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The company had revenue of $533.00 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the previous year, the company posted $0.57 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. Qiagen has set its FY 2025 guidance at 2.380-2.380 EPS. Q4 2025 guidance at 0.600-0.600 EPS. As a group, equities analysts anticipate that Qiagen N.V. will post 2.26 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on QGEN shares. UBS Group lifted their price objective on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Weiss Ratings restated a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Barclays set a $53.00 price target on shares of Qiagen and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Cowen restated a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. Finally, Wall Street Zen upgraded shares of Qiagen from a “hold” rating to a “buy” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Qiagen presently has an average rating of “Hold” and a consensus price target of $49.69.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.